Rani Therapeutics — Third Quarter 2026 Earnings Summary

Rani Therapeutics Holdings, Inc. reported a net loss of $8.8 million for the third quarter ended September 30, 2026, driven by increased research and development expenses of $6.0 million. The company holds $45.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations through the end of 2027. In October 2026, the RaniPill platform technology was accepted into the FDA's Emerging Technology Program to facilitate early regulatory engagement. Additionally, enrollment continues in the Phase 1a expansion cohort for the RT-114 study, with data anticipated by the end of 2026.